Atlas Trials

Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation

Clinical trial NCT03856697 · UNKNOWN

Trial details

NCT number
NCT03856697
Sponsor
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Advanced Non-small Cell Lung Cancer
Start date
2019-03-01
Primary completion
2022-03-01
Enrollment
406

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.